REFRACTORY MALIGNANT SOLID NEOPLASM
Clinical trials for REFRACTORY MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested two drugs, cabozantinib and pamiparib, in 44 people with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes that help cance…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New pill shows promise against Hard-to-Treat cancers with specific gene flaw
Disease control CompletedThis study tested an oral drug called infigratinib in 17 adults with advanced or spreading solid tumors that have certain FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The main goal was to see how many patients' tumors shrank or d…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a combination of two drugs, sapanisertib and ziv-aflibercept, in 83 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goal was to find the safest dose and identify side effects. The approach aims to slow t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in early trial
Disease control CompletedThis study tested a drug called samotolisib in 18 children and teens whose cancers (solid tumors, lymphoma, or related disorders) had spread, returned, or stopped responding to treatment. Only those with specific gene mutations (TSC or PI3K/MTOR) were eligible. The goal was to se…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:02 UTC